Dr. Ningning Lu 卢宁宁
Chief Physician
Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy for malignant tumors, including prostate cancer, sarcoma, bladder cancer, renal cancer, testicular tumors, oligometastases, breast cancer, pediatric tumors, gastrointestinal tumors, and lymphoma. Expertise in MR-linac adaptive hypofractionated therapy and stereotactic body radiation therapy.
Dr. Lu holds a PhD in Oncology from Peking Union Medical College and serves as Deputy Chief Physician in the Department of Radiation Oncology at Cancer Hospital, Chinese Academy of Medical Sciences. Dr. Lu completed clinical fellowship training at Princess Margaret Cancer Centre in Canada, focusing on comprehensive treatment of prostate, bladder, renal, testicular cancers, and sarcoma. Dr. Lu has conducted research exchanges in the US and Canada.
Professional roles
- Member, Standing Committee of Pediatric Malignant Tumor Professional Committee, National Health Commission
- Secretary-General, Radiotherapy Professional Committee, National Health Commission
- Member, Prostate Cancer Quality Control Expert Committee, National Cancer Center
- Editorial Board Member, CDTM (Chronic Diseases and Translational Medicine) UroPrecision
Name order: in Chinese the family name comes first (Lu Ningning). Papers usually list the name as Ningning Lu or Lu N.
Selected publications
112 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- Transl Cancer Res, 2026 (senior author): Tumor habitat characteristics derived from intravoxel incoherent motion for early response assessment in soft tissue sarcoma undergoing neoadjuvant radiotherapy and targeted therapy: a phase II study. PubMed 41815116
- Radiat Oncol, 2026 (senior author): Magnetic resonance-guided simultaneous multi-focal adaptive radiotherapy for prostate, pElvis & metastases (MRgSMART-PEM) in prostate cancer: a prospective phase II study. PubMed 41689033
- Adv Radiat Oncol, 2024 (senior author): Optical Surface-guided Radiation Therapy for Upper and Lower Limb Sarcomas: An Analysis of Setup Errors and Clinical Target Volume-To-Planning Target Volume Margins. PubMed 39026611
- Chronic Dis Transl Med, 2024 (senior author): Adaptive ultra-hypofractionated whole-pelvic radiotherapy in high-risk and very high-risk prostate cancer on 1.5-Tesla MR-Linac: Estimated delivered dose and early toxicity results. PubMed 38450305
- Eur Radiol, 2023 (senior author): Predicting pathological complete response of neoadjuvant radiotherapy and targeted therapy for soft tissue sarcoma by whole-tumor texture analysis of multisequence MRI imaging. PubMed 36580095
- Front Oncol, 2023 (senior author): Assessment of delivered dose in prostate cancer patients treated with ultra-hypofractionated radiotherapy on 1.5-Tesla MR-Linac. PubMed 36741014
- PLoS One, 2015 (first author): Postoperative Capecitabine with Concurrent Intensity-Modulated Radiotherapy or Three-Dimensional Conformal Radiotherapy for Patients with Stage II and III Rectal Cancer. PubMed 25915948
- Int J Radiat Oncol Biol Phys, 2012 (first author): Dosimetric and clinical outcomes of involved-field intensity-modulated radiotherapy after chemotherapy for early-stage Hodgkin's lymphoma with mediastinal involvement. PubMed 22436783
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion